BDX Unveils 'Excellence Unleashed' Strategy, Targets $4B Cash from Waters Deal

Ticker: BDX · Form: DEF 14A · Filed: 2025-12-18T00:00:00.000Z

Sentiment: bullish

Topics: MedTech, Strategic Transformation, Shareholder Value, Dividend Aristocrat, Portfolio Optimization, Innovation Pipeline, Capital Allocation

Related Tickers: BDX, WAT

TL;DR

**BDX is shedding non-core assets and buying back billions, signaling a bullish bet on its MedTech future and a tighter, more profitable operation.**

AI Summary

Becton, Dickinson and Company (BDX) is concluding its BD2025 strategy and launching 'Excellence Unleashed,' focusing on accelerating growth, breakthrough innovation, and operational excellence. The company reported record fiscal year 2025 revenue of $21.8 billion, GAAP EPS of $5.82, and adjusted diluted EPS of $14.40, alongside approximately $3.4 billion in net cash from continuing operations. A key strategic move is the agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corp. via a Reverse Morris Trust transaction, which is expected to generate approximately $4 billion in cash proceeds. BD plans to allocate at least half of these proceeds to share repurchases and the remainder to debt repayment, aiming for a ~2.5x net leverage target. The company returned $2.2 billion to shareholders in fiscal year 2025 through repurchases and dividends, marking its 54th consecutive year of dividend increases. BD Excellence, its lean operating system, drove an 8% year-over-year productivity increase and a 50% reduction in manufacturing non-conformances, contributing to margin expansion and the lowest CapEx-to-revenue ratio in over a decade.

Why It Matters

BDX's strategic pivot to a pure-play MedTech leader, divesting its Biosciences and Diagnostic Solutions, signals a sharper focus on high-growth medical device markets like Biologic Drug Delivery and Advanced Patient Monitoring. This move, coupled with a planned $2 billion in share repurchases from the $4 billion Waters Corp. transaction proceeds, could significantly boost shareholder value and improve capital efficiency. For employees, the new vertical business unit operating model aims for greater customer proximity, potentially fostering innovation and market responsiveness. Competitively, this streamlined portfolio positions BDX to better compete with specialized MedTech rivals, while its 54th consecutive dividend increase underscores its commitment to consistent shareholder returns.

Risk Assessment

Risk Level: medium — The 'Excellence Unleashed' strategy relies heavily on successful execution of new commercial capabilities and a high-impact innovation pipeline, which inherently carries market adoption and R&D risks. While the Waters RMT transaction is expected to generate approximately $4 billion in cash, the actual amount is subject to adjustments for cash, working capital, and indebtedness, introducing a degree of financial uncertainty. Furthermore, the company's ability to achieve its ~2.5x net leverage target depends on effective debt repayment and cash flow management post-transaction.

Analyst Insight

Investors should closely monitor the closing of the Waters RMT transaction and the subsequent deployment of the approximately $4 billion cash proceeds, particularly the promised share repurchases, as these actions could provide a near-term catalyst for BDX stock. Evaluate the progress of the 'Excellence Unleashed' strategy, specifically the impact of new product launches and commercial execution on revenue growth and margin expansion, to gauge long-term value creation.

Financial Highlights

revenue
$21.8B
eps
$5.82

Executive Compensation

NameTitleTotal Compensation
Tom PolenChairman, Chief Executive Officer and President

Key Numbers

Key Players & Entities

FAQ

What is Becton, Dickinson and Company's new strategic vision?

Becton, Dickinson and Company's new strategic vision is 'Excellence Unleashed,' which aims to deliver world-class commercial execution, a high-impact innovation pipeline, and unmatched quality and supply reliability, building on the success of its BD2025 strategy.

How much revenue did Becton, Dickinson and Company generate in fiscal year 2025?

Becton, Dickinson and Company achieved record fiscal year 2025 revenue of $21.8 billion, alongside a GAAP EPS of $5.82 and a record adjusted diluted EPS of $14.40.

What is the significance of the Waters Corp. transaction for Becton, Dickinson and Company?

The Waters Corp. transaction, a Reverse Morris Trust, simplifies Becton, Dickinson and Company's portfolio, transitioning it to a dedicated medical technology company. It is expected to generate approximately $4 billion in cash proceeds, with at least half allocated to share repurchases and the balance to debt repayment.

How is Becton, Dickinson and Company returning value to shareholders?

Becton, Dickinson and Company returned $2.2 billion to shareholders in fiscal year 2025 through share repurchases and dividends. The company also boasts its 54th consecutive year of dividend increases, maintaining its status as an S&P 500 Dividend Aristocrat.

What are the key operational improvements driven by BD Excellence at Becton, Dickinson and Company?

BD Excellence has driven robust improvements, including an 8% year-over-year increase in productivity and a 50% reduction in manufacturing non-conformances, leading to record highs in quality and the lowest CapEx-to-revenue ratio in over a decade for Becton, Dickinson and Company.

Who is Tom Polen and what is his role at Becton, Dickinson and Company?

Tom Polen is the Chairman, Chief Executive Officer, and President of Becton, Dickinson and Company. He is leading the company's strategic transformation and the launch of the 'Excellence Unleashed' vision.

What is Becton, Dickinson and Company's target net leverage?

Becton, Dickinson and Company continues to make progress towards achieving a ~2.5x net leverage target, supported by its enhanced capital allocation strategy and debt repayment plans following the Waters RMT transaction.

What new technologies is Becton, Dickinson and Company introducing?

Becton, Dickinson and Company has launched BD Incada, an AI-enabled platform to unify device data, and its next-generation BD Pyxis Pro Medication Dispensing platform, designed for smarter, more secure medication storage and faster access at the point of care.

What is the purpose of Proposal 4 at Becton, Dickinson and Company's 2026 Annual Meeting?

Proposal 4 seeks shareholder approval for an amendment to Becton, Dickinson and Company's 2004 Employee and Director Equity-Based Compensation Plan to increase the number of authorized shares available for awards by 3,935,000 shares, from 51,700,000 to 55,635,000, to attract and retain talent.

How many directors are standing for re-election at Becton, Dickinson and Company's 2026 Annual Meeting?

Thirteen directors are standing for re-election at Becton, Dickinson and Company's 2026 Annual Meeting. Catherine M. Burzik is not standing for re-election due to reaching the mandatory director retirement age, reducing the board size to 13 members.

Risk Factors

Industry Context

Becton, Dickinson and Company operates in the highly competitive and dynamic medical technology sector. Key trends include the increasing demand for advanced diagnostics, personalized medicine, and digital health solutions. Major competitors include companies like Medtronic, Abbott Laboratories, and Thermo Fisher Scientific, all investing heavily in innovation and global expansion. The industry is characterized by significant R&D investment, stringent regulatory oversight, and a focus on operational efficiency to drive growth and profitability.

Regulatory Implications

BD faces significant regulatory scrutiny from global health authorities such as the FDA, EMA, and others. Compliance with evolving regulations regarding medical device manufacturing, data privacy, and product safety is paramount. The company's ability to maintain high quality standards, as evidenced by its reduction in manufacturing non-conformances, is crucial for avoiding costly recalls, fines, and reputational damage.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]
  5. [object Object]

Key Dates

Glossary

DEF 14A
A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual shareholder meeting, including director nominations, executive compensation, and other corporate governance matters. (This document is the primary source of information for shareholders to make informed voting decisions.)
Reverse Morris Trust (RMT)
A tax-efficient transaction structure where a company spins off a business unit into a new entity, which then merges with another company. Shareholders of the spun-off unit typically receive shares in the merged entity. (BD is using this structure to combine its Biosciences and Diagnostic Solutions business with Waters Corp., aiming to unlock value and create a dedicated life sciences company.)
BD Excellence
BD's lean operating system designed to drive productivity, quality, and operational efficiency across the company's manufacturing and supply chain. (This initiative has been instrumental in improving operational performance, reducing costs, and enhancing margins, as evidenced by an 8% productivity increase and a 50% reduction in manufacturing non-conformances.)
GAAP EPS
Earnings Per Share calculated according to Generally Accepted Accounting Principles. It represents the portion of a company's profit allocated to each outstanding share of common stock. (Provides a standardized measure of profitability. BD reported $5.82 GAAP EPS for FY2025.)
Adjusted Diluted EPS
Earnings Per Share that excludes certain items, such as restructuring costs, acquisition-related expenses, or other non-recurring items, to provide a clearer view of ongoing operational performance. (BD reported record adjusted diluted EPS of $14.40 for FY2025, indicating strong underlying business performance.)
Net Leverage Target
A financial metric that measures a company's total debt relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). A target indicates the desired level of debt for financial flexibility and stability. (BD aims for a net leverage target of approximately 2.5x post-transaction, guiding its debt repayment strategy.)

Year-Over-Year Comparison

The previous filing likely focused on the ongoing BD2025 strategy and its progress. This year's filing highlights the culmination of that strategy, record FY2025 financial performance ($21.8B revenue, $14.40 adj. EPS), and the launch of the new 'Excellence Unleashed' strategy. A significant shift is the planned divestiture of Biosciences and Diagnostic Solutions via an RMT transaction, a major portfolio change not present in prior filings. Operational improvements driven by BD Excellence, such as an 8% productivity increase and 50% reduction in manufacturing non-conformances, are emphasized as foundational for future growth, likely building on previous years' operational focus.

Filing Stats: 4,344 words · 17 min read · ~14 pages · Grade level 15 · Accepted 2025-12-18 11:25:37

Key Financial Figures

Filing Documents

From the Filing

bdx-20251217 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Becton, Dickinson and Company (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, New Jersey 07417-1880 www.bd.com December 18, 2025 Fellow shareholders: This year marks the culmination of our BD2025 strategy and the beginning of a bold new vision to Unleash Excellence across BD's business. We aim to deliver world-class commercial execution, a high-impact innovation pipeline and unmatched quality and supply reliability – all in the service of a new chapter of growth. Over the past five years, BD has achieved the most prolific period of organic growth in our 128-year history, built and scaled multiple unique high-growth platforms and developed a strong innovation pipeline in attractive end markets. During this period, we became a leader among our peer group in gross and operating margin expansion – driven by the creation and scale of BD Excellence, our lean operating system. As the capstone of our BD2025 strategy, we announced the agreement to combine our Biosciences and Diagnostic Solutions business with Waters Corp. and the transition of BD to a dedicated medical technology company upon closing. This strategic move simplifies our portfolio and unlocks value for our shareholders through ownership in the new life sciences company. The transaction also enhances our capital allocation framework, with a commitment to allocating at least half of the expected $4 billion cash proceeds for share repurchases with the balance for debt repayment following the closing. These advances provide momentum as we launch our new growth strategy – Excellence Unleashed – across three strategic priorities: Compete – We expect to accelerate growth and drive an exceptional customer experience through world-class commercial capabilities, technologies and a culture of relentless execution. Innovate – We will capitalize on our unique position to create and deliver breakthrough innovations in high-growth markets, leveraging the power of AI, robotics and new material science to advance healthcare globally. We will meaningfully increase the value and pace of our pipeline through innovation excellence and investment. Deliver – We will deliver exceptional quality, reliable supply and consistent cash flow growth. Operational excellence is our foundation for trust and enables reinvestment in commercial and innovation capabilities. Our strategy is to achieve excellence everywhere. We are already making progress, including introducing a new vertical business unit operating model to drive greater customer proximity, a relentless focus on commercial excellence, the most impactful pipeline in BD history and record levels for operational efficiency, quality and reliability. The success of our last five years sets the foundation for our ability to raise our standard even higher, create more value and help more patients than ever before. Thank you for your continued support as we capitalize on the opportunity ahead. I look forward to your participation in the 2026 Annual Meeting of Shareholders. Sincerely, Tom Polen Chairman, Chief Executive Officer and President 2026 Notice of Annual Meeting and Proxy Statement 1 Table of contents Letter to our shareholders 1 Notice of annual meeting of shareholders 3 Proxy statement overview 4 Proposal 1: Election of directors 13 Director n ominees —skills and experience 14 Director n ominees 15 Board refreshment, nomination and representation 22 Shareholder recommendations 25 Proxy access nominations 25 Board leadership structure 25 Corporate governance 26 The B oard and committees of the B oard 26 Board practices, policies and processes 40 Non-management director compensation 44 Proposal 2: Ratification of selection of independent registered public accounting firm 47 Pre-approval of audit and non-audit services 47 Report of the audit committee 48 Proposal 3: Advisory vote to approve named executive officer compensation 49 Compensation discussion and analysis 50 Executive summary 50 Our compensation objectives and practices 50 Design and structure of 202 5 executive co

View on Read The Filing